{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:12:58Z","timestamp":1791259978503,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41582-025-01141-3","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:03:32Z","timestamp":1758110612000},"page":"664-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis"],"prefix":"10.1038","volume":"21","author":[{"given":"Marcello","family":"Moccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-8496","authenticated-orcid":false,"given":"Alan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00270-4","author":"X Montalban","year":"2025","unstructured":"Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4 (2025).","journal-title":"Lancet Neurol."},{"key":"1141_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ana.27145","volume":"97","author":"WJ Brownlee","year":"2025","unstructured":"Brownlee, W. J. et al. Towards a unified set of diagnostic criteria for multiple sclerosis. Ann. Neurol. 97, 571\u2013582 (2025).","journal-title":"Ann. Neurol."},{"key":"1141_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"1141_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/13524585241272046","volume":"30","author":"M Petracca","year":"2024","unstructured":"Petracca, M. et al. Brain reserve and timing of clinical onset in multiple sclerosis. Mult. Scler. 30, 1290\u20131295 (2024).","journal-title":"Mult. Scler."},{"key":"1141_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/13524585231225848","volume":"30","author":"A Vidal-Jordana","year":"2024","unstructured":"Vidal-Jordana, A., Sastre-Garriga, J., Tintor\u00e9, M., Rovira, \u00c0. & Montalban, X. Optic nerve topography in multiple sclerosis diagnostic criteria: existing knowledge and future directions. Mult. Scler. 30, 139\u2013149 (2024).","journal-title":"Mult. Scler."},{"key":"1141_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/13524585221134217","volume":"29","author":"H Hegen","year":"2023","unstructured":"Hegen, H. et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a consensus statement. Mult. Scler. 29, 182\u2013195 (2023).","journal-title":"Mult. Scler."},{"key":"1141_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200253","volume":"11","author":"S Borrelli","year":"2024","unstructured":"Borrelli, S. et al. Central vein sign, cortical lesions, and paramagnetic rim lesions for the diagnostic and prognostic workup of multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 11, e200253 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1141_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14737175.2022.2143265","volume":"22","author":"MS Martire","year":"2022","unstructured":"Martire, M. S., Moiola, L., Rocca, M. A., Filippi, M. & Absinta, M. What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis? Expert Rev. Neurother. 22, 829\u2013837 (2022).","journal-title":"Expert Rev. Neurother."},{"key":"1141_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaneurol.2023.4737","volume":"81","author":"A Cagol","year":"2024","unstructured":"Cagol, A. et al. Diagnostic performance of cortical lesions and the central vein sign in multiple sclerosis. JAMA Neurol. 81, 143\u2013153 (2024).","journal-title":"JAMA Neurol."},{"key":"1141_CR10","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1212\/WNL.0000000000207664","volume":"101","author":"A Cobo-Calvo","year":"2023","unstructured":"Cobo-Calvo, A. et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology 101, e1280\u2013e1292 (2023).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01141-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01141-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01141-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:03:29Z","timestamp":1764248609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01141-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01141-3","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"17 September 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. has received honoraria from Abbvie, Biogen, BMS Celgene, Ipsen, Janssen, Merck, Novartis, Roche and Sanofi-Genzyme. O.C. is a member of an independent data and safety monitoring board for Novartis; has given a teaching talk in a local symposium for Merck; and has contributed to an advisory board for Biogen. A.T. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}